Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Keywords: regadenoson chronic kidney disease renal failure lexiscan aminophylline SPECT Myocardial Perfusion Imaging pharmacologic stress test Patients with stage IV or V chronic kidney disease being assessed with nuclear stress testing of the heart using the stress agent regadenoson (Lexiscan ®)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 300
Healthy volunteers: no

Brief summary:
The routine administration of 75 mg of intravenous aminophylline in patients with severe chronic kidney disease undergoing a nuclear stress test with regadenoson (Lexiscan®) can reduce or eliminate the incidence of diarrhea and other side effects related to regadenoson.

Detailed description:
Approximately 300 patients with severe chronic kidney disease who are referred for a nuclear stress testing of the heart with regadenoson (Lexiscan®) will be recruited to participate in the study. Following regadenoson (administered as part of a stress routine test protocol) participants will receive either aminophylline (75 mg - intravenously) or a matching inactive placebo (sterile salt water) injection. Participants will be surveyed for gastrointestinal symptoms and other side effects related to regadenoson. The frequency and severity of such side effects will be compared between the two study groups (aminophylline vs. placebo).

Arms:
arm 1: 75 mg of intravenous aminophylline. arm 2: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.

Interventions: intervention 1: Aminophylline intervention 2: Placebo
Intervention descriptions: intervention 1: 75 mg of intravenous aminophylline intervention 2: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.

Protocol document: